These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 27544319)

  • 21. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature.
    Ito MK
    Atherosclerosis; 2015 Oct; 242(2):647-56. PubMed ID: 26296750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypertriglyceridemia: associated risks and effect of drug treatment.
    Jonkers IJ; Smelt AH; van der Laarse A
    Am J Cardiovasc Drugs; 2001; 1(6):455-66. PubMed ID: 14728004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug therapy for hypertriglyceridemia: fibrates and omega-3 fatty acids.
    Toth PP; Dayspring TD; Pokrywka GS
    Curr Atheroscler Rep; 2009 Jan; 11(1):71-9. PubMed ID: 19080732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triglyceride-Rich Lipoproteins and Remnants: Targets for Therapy?
    Dallinga-Thie GM; Kroon J; Borén J; Chapman MJ
    Curr Cardiol Rep; 2016 Jul; 18(7):67. PubMed ID: 27216847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triglycerides and residual risk.
    Vallejo-Vaz AJ; Corral P; Schreier L; Ray KK
    Curr Opin Endocrinol Diabetes Obes; 2020 Apr; 27(2):95-103. PubMed ID: 32073428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.
    Berglund L; Brunzell JD; Goldberg AC; Goldberg IJ; Stalenhoef A
    Best Pract Res Clin Endocrinol Metab; 2014 Jun; 28(3):423-37. PubMed ID: 24840268
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia.
    Patel AA; Budoff MJ
    Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):145-9. PubMed ID: 26825470
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Triglycerides in Atherosclerosis: Recent Pathophysiologic Insights and Therapeutic Implications.
    Akivis Y; Alkaissi H; McFarlane SI; Bukharovich I
    Curr Cardiol Rev; 2024; 20(2):39-49. PubMed ID: 38288833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
    Breuer HW
    Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.
    Ganda OP; Bhatt DL; Mason RP; Miller M; Boden WE
    J Am Coll Cardiol; 2018 Jul; 72(3):330-343. PubMed ID: 29935936
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Residual risk: The roles of triglycerides and high density lipoproteins].
    Grammer T; Kleber M; Silbernagel G; Scharnagl H; März W
    Dtsch Med Wochenschr; 2016 Jun; 141(12):870-7. PubMed ID: 27305303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia.
    Christian JB; Arondekar B; Buysman EK; Jacobson TA; Snipes RG; Horwitz RI
    Am J Med; 2014 Jan; 127(1):36-44.e1. PubMed ID: 24384100
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CE: Triglycerides: Do They Matter?
    Scordo K; Pickett KA
    Am J Nurs; 2017 Jan; 117(1):24-31. PubMed ID: 28030403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of Mild-to-Moderate Hypertriglyceridemia.
    Pulipati VP; Brinton EA; Hatipoglu B
    Endocr Pract; 2022 Nov; 28(11):1187-1195. PubMed ID: 35850450
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reducing residual cardiovascular risk in Europe: Therapeutic implications of European medicines agency approval of icosapent ethyl/eicosapentaenoic acid.
    Chapman MJ; Zamorano JL; Parhofer KG
    Pharmacol Ther; 2022 Sep; 237():108172. PubMed ID: 35304222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous injection of apolipoprotein A-V reconstituted high-density lipoprotein decreases hypertriglyceridemia in apoav-/- mice and requires glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1.
    Shu X; Nelbach L; Weinstein MM; Burgess BL; Beckstead JA; Young SG; Ryan RO; Forte TM
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2504-9. PubMed ID: 20966404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
    Chapman MJ; Ginsberg HN; Amarenco P; Andreotti F; Borén J; Catapano AL; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Nordestgaard BG; Ray KK; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A; Watts GF;
    Eur Heart J; 2011 Jun; 32(11):1345-61. PubMed ID: 21531743
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Childhood Hypertriglyceridemia: Is It Time for a New Approach?
    Sunil B; Ashraf AP
    Curr Atheroscler Rep; 2022 Apr; 24(4):265-275. PubMed ID: 35107763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is hypertriglyceridemia atherogenic?
    Roubille F; Sultan A; Huet F; Leclercq F; Macia JC; Gervasoni R; Delseny D; Akodad M; Roubille C
    Presse Med; 2018 Sep; 47(9):757-763. PubMed ID: 30262206
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.
    Borén J; Packard CJ; Taskinen MR
    Front Endocrinol (Lausanne); 2020; 11():474. PubMed ID: 32849270
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.